<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The presence of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> are known risk markers for macrovascular disease in patients with and without type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This study has examined whether these also were predictors of micro- and macrovascular complications in type 1 diabetic patients participating in the <z:mp ids='MP_0002055'>Diabetes</z:mp> Control and Complications Trial (DCCT) </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: International <z:mp ids='MP_0002055'>Diabetes</z:mp> Federation (IDF) criteria were used to identify the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in 1,337 Caucasian DCCT patients at baseline </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> was calculated using their estimated <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal rate (eGDR) </plain></SENT>
<SENT sid="4" pm="."><plain>Insulin dose (units/kg) was also used as a separate marker of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The eGDR (but not insulin dose or <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>) at baseline strongly predicted the development of <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (hazard ratios 0.75, 0.88, and 0.70, respectively, per mg x kg(-1) x min(-1) change; P &lt; 0.001, P = 0.005, and P = 0.002, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>Through mainly <z:mp ids='MP_0005456'>weight gain</z:mp>, the prevalence of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> increased steadily from baseline to year 9 in conventionally treated (from 15.5 to 27.2%) and especially in the intensively treated (from 13.7 to 45.4%) patients </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Higher <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> at baseline in the DCCT (as estimated by eGDR) was associated with increased subsequent risk of both micro- and macrovascular complications </plain></SENT>
<SENT sid="8" pm="."><plain>Insulin dose and the presence of IDF-defined <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> were poor predictors by comparison </plain></SENT>
<SENT sid="9" pm="."><plain>Although intensive treatment was associated with a higher subsequent prevalence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, the benefits of improved glycemia appear to outweigh the risks related to development of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
</text></document>